Azoximer bromide, sold by the trade name Polyoxidonium, is a macromolecular compound with high-molecular weight and high immunomodulating activity. It is used in Russia and CIS in treatment and prophylaxis of diseases connected with damage of immune system. It is a N-oxidized polyethylene–piperazine derivative.

Azoximer bromide is registered in US Patent-5503830 from 1996, in the Russian Federation from 1996, under registration number 96/302/9, FS 42-3906-00.

The global Polyoxidonium market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Polyoxidonium volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Polyoxidonium market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Polyoxidonium Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Lyophilizate
Suppositories
Tablets

Segment by Application
Chronic Infections
Acute Infections
Allergic Diseases
Severe Septic States
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
NPO Petrovax Pharm
Aversi
Microgen
Anatoly Smorodintsev
Panacea Biotec Ltd